Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?
作者信息
Menis Jessica, Remon Jordi
机构信息
Medical Oncology Department, University and Hospital Trust of Verona, Verona, Italy.
Paris-Saclay University, Institut Gustave Roussy, Villejuif, France.
出版信息
Lancet Respir Med. 2023 Oct;11(10):857-859. doi: 10.1016/S2213-2600(23)00216-3. Epub 2023 May 24.
Abstract
摘要
相似文献
1
Befotertinib-a viable alternative in EGFR-mutant advanced NSCLC?贝福替尼——EGFR突变型晚期非小细胞肺癌的可行替代方案？
Lancet Respir Med. 2023 Oct;11(10):857-859. doi: 10.1016/S2213-2600(23)00216-3. Epub 2023 May 24.
2
Treatment of advanced EGFR-mutant NSCLC patients: Sequencing matters.晚期表皮生长因子受体（EGFR）突变型非小细胞肺癌（NSCLC）患者的治疗：测序至关重要。
Pulmonology. 2019 Sep-Oct;25(5):306-309. doi: 10.1016/j.pulmoe.2019.04.005. Epub 2019 Jun 7.
3
Befotertinib: First Approval.贝福替尼：首次获批
Drugs. 2023 Oct;83(15):1433-1437. doi: 10.1007/s40265-023-01946-w.
4
EGFR Tyrosine Kinase Inhibitor Monotherapy Should Remain the Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.表皮生长因子受体酪氨酸激酶抑制剂单药治疗应仍是晚期表皮生长因子受体突变型非小细胞肺癌的标准一线治疗方案。
J Thorac Oncol. 2021 Nov;16(11):1793-1797. doi: 10.1016/j.jtho.2021.08.015.
5
Efficacy and Safety of Befotertinib (D-0316) in Patients With EGFR T790M-Mutated NSCLC That Had Progressed After Prior EGFR Tyrosine Kinase Inhibitor Therapy: A Phase 2, Multicenter, Single-Arm, Open-Label Study.贝福替尼（D-0316）治疗 EGFR T790M 突变 NSCLC 患者的疗效和安全性：一项 II 期、多中心、单臂、开放标签研究。
在接受过 EGFR 酪氨酸激酶抑制剂治疗后进展的 EGFR T790M 突变 NSCLC 患者中评估贝福替尼（D-0316）的疗效和安全性的多中心、单臂、开放标签的 II 期研究。
J Thorac Oncol. 2022 Oct;17(10):1192-1204. doi: 10.1016/j.jtho.2022.06.002. Epub 2022 Jun 18.
6
EGFR Combination Therapy Should Become the New Standard First-Line Treatment in Advanced EGFR-Mutant NSCLC.表皮生长因子受体联合疗法应成为晚期表皮生长因子受体突变型非小细胞肺癌新的一线标准治疗方案。
J Thorac Oncol. 2021 Nov;16(11):1788-1792. doi: 10.1016/j.jtho.2021.06.004.
7
Third-generation EGFR-TKIs—a new hope for NSCLC.第三代表皮生长因子受体酪氨酸激酶抑制剂——非小细胞肺癌的新希望。
Lancet Respir Med. 2014 Jul;2(7):520. doi: 10.1016/s2213-2600(14)70095-5.
8
Response to 'Clinical outcomes in NSCLC patients with EGFR mutations: pooled analysis'
(Paz-Ares et al., J Cell Mol Med. 2010; 14: 51-69).对《EGFR 突变的非小细胞肺癌患者的临床结局：汇总分析》的回应（帕兹 - 阿雷斯等人，《细胞与分子医学杂志》。2010 年；14：51 - 69）
J Cell Mol Med. 2010 Nov;14(11):2693-4. doi: 10.1111/j.1582-4934.2010.01188.x.
9
New data highlighting the efficacy and safety outcomes of third-generation EGFR-TKI in NSCLC patients with rare EGFR mutations.新数据凸显了第三代表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）在具有罕见EGFR突变的非小细胞肺癌（NSCLC）患者中的疗效和安全性结果。
Thorac Cancer. 2020 Mar;11(3):495-497. doi: 10.1111/1759-7714.13334. Epub 2020 Jan 28.
10
Afatinib in Osimertinib-Resistant EGFR ex19del/T790M/P794L Mutated NSCLC.阿法替尼用于奥希替尼耐药的EGFR外显子19缺失/T790M/P794L突变的非小细胞肺癌
J Thorac Oncol. 2018 Sep;13(9):e161-e163. doi: 10.1016/j.jtho.2018.04.020. Epub 2018 Apr 25.
引用本文的文献
1
Profiling and Optimizing Targeted Covalent Inhibitors through EGFR-Guided Studies.通过表皮生长因子受体（EGFR）导向研究对靶向共价抑制剂进行分析和优化
J Med Chem. 2025 Aug 28;68(16):17917-17932. doi: 10.1021/acs.jmedchem.5c01661. Epub 2025 Aug 13.
Zotero 插件